- Home
- GLRE vs ALT Comparison
GLRE vs ALT Comparison
Compare GLRE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | ALT |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.5M | 576.0M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLRE | ALT |
|---|---|---|
| Price | $14.14 | $5.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.33 |
| AVG Volume (30 Days) | 116.7K | ★ 3.5M |
| Earning Date | 11-03-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $661,540,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.57 | $2.90 |
| 52 Week High | $15.07 | $9.59 |
Technical Indicators
Market Signals| Indicator | GLRE | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 70.66 | 61.41 |
| Support Level | $13.57 | $5.03 |
| Resistance Level | $13.99 | $5.83 |
| Average True Range (ATR) | 0.27 | 0.38 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 100.00 | 47.00 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.